Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2253-2258

  Styczynski, Jan ^a   Kurylak, Andrzej ^a   Wysocki, Mariusz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Betamethasone; Cortivazol; Dexamethasone; Glucocorticoids; Prednisolone; Resistance

Indexed keywords

BETAMETHASONE; CORTIVAZOL; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CELL CYCLE; CELL VIABILITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG BINDING SITE; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFANT; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADOLESCENT; CELL CYCLE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOCYTES; MALE; PREDNISOLONE; PREGNATRIENES; PROGNOSIS;

EID: 21344448820     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, van Wering ER and Veerman AJ: Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 12: 1344-1348, 1998.
2. Tissing WJ, Meijerink JP, den Boer ML and Pieters R: Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 17: 17-25, 2003.
3. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E and Riehm H: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14: 2205-2222, 2000.
4. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B and Henze G: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 799: 151-160, 1987.
5. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER and Van Der Does-Van Den Berg A: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90: 2723-2729, 1997.
6. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A and Veerman AJ: Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92: 259-266, 1998.
7. Lauten M, Cario G, Asgedom G, Welte K and Schrappe M: Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. Haematologica 88: 1253-1258, 2003.
8. Lauten M, Beger C, Gerdes K, Asgedom G, Kardinal C, Welte K and Schrappe M: Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. Leukemia 17: 1551-1556, 2003.
9. Bailey S, Hall AG, Pearson AD, Reid MM and Redfern CP: Glucocorticoid resistance and the AP-1 transcription factor in leukaemia. Adv Exp Med Biol 457: 615-619, 1999.
10. Kofler R: The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 114: 1-7, 2000.
11. Yetgin S, Tuncer MA, Cetin M, Gumruk F, Yenicesu I, Tune B, Oner AF, Toksoy H, Koc A, Asian D, Ozyurek E, Olcay L, Atahan L, Tuncbilek E and Gurgey A: Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 17: 328-333, 2003.
12. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ and Sallan SE: Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 19: 1040-1046, 2001.
13. Schlechte JA, Simons SS, Lewis DA and Thompson EB: [3H]cortivazol: a unique high affinity ligand for the glucocorticoid receptor. Endocrinology 117: 1355-1362, 1985.
14. Gaynon PS and Carrel AL: Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 457: 593-605, 1999.
15. Yoshikawa N, Makino Y, Okamoto K, Morimoto C, Makino I and Tanaka H: Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor. J Biol Chem 277: 5529-5540, 2002.
16. Schlechte JA and Schmidt TJ: Use of [3H]cortivazol to characterize glucocorticoid receptors in a dexamethasone-resistant human leukemic cell line. J Clin Endocrinol Metab 64: 441-446, 1987.
17. Kralli A, Bohen SP and Yamamoto KR: LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc Natl Acad Sci USA 92: 4701-4705, 1995.
18. Larsson S, Brattsand R and Linden M: Interleukin-2 and -4 induce resistance of granulocyte-macrophage colony-stimulating factor to corticosteroids. Eur J Pharmacol 334: 265-271, 1997.
19. Juneja HS, Harvey WH, Brasher WK and Thompson EB: Successful in vitro purging of leukemic blasts from marrow by cortivazol, a pyrazolosteroid: a preclinical study for autologous transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leukemia 9: 1771-1778, 1995.
20. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM and Bleyer WA: Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 82: 600-612, 1998.
21. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H and Riehm H: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95: 3310-3322, 2000.
22. Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M and Veerman AJ: In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 110: 813-818, 2000.
23. DeRijk R and Sternberg EM: Corticosteroid resistance and disease. Ann Med 29: 79-82, 1997.
24. Lamberts SW, Huizenga AT, de Lange P, de Jong FH and Koper J: Clinical aspects of glucocorticoid sensitivity. Steroids 61: 157-160, 1996.
25. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R and Henze G: In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86: 3861-3868, 1995.
26. Kaspers GJ, Pieters R, Klumper E, De Waal FC and Veerman AJ: Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 13: 187-201, 1994.
27. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, Gadner H, Riehm H and Schrappe M: Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94: 1209-1217, 1999.
28. Ranney HM and Gellhorn A: The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas. Am J Med 22: 405-413, 1957.
29. Styczynski J and Wysocki M: Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22: 963-964, 2004.
30. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ and Janka-Schaub GE: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21: 3262-3268, 2003.